Fairness Opinion for Vifor Pharma

On 14 December 2021, CSL Limited announced its offer to acquire all publicly held registered shares of Vifor Pharma Ltd. (Vifor Pharma) through its subsidiary CSL Behring AG (CSL) by means of a public takeover. CSL is offering USD 179.25 (approximately CHF 165 at the time of announcement) in cash per share of Vifor Pharma. In addition, an expected ordinary dividend of CHF 2 is expected to be paid to shareholders. With a total transaction volume of approximately CHF 11 billion, this represents the third largest cash offer ever made in Switzerland.

The transaction is supposed to complement CSL’s existing therapeutic focus areas including hematology and thrombosis, cardiovascular-metabolic and transplant. In addition, CSL’s global scale, R&D capabilities and resources should augment the delivery of Vifor Pharma’s products to patients globally.

Support by IFBC

‍IFBC was mandated by the board of directors of Vifor Pharma to prepare a Fairness Opinion assessing the financial fairness of the takeover offer made by CSL Behring AG. As a qualified evaluator pursuant to Article 30(6) Takeover Ordinance, IFBC is suitably qualified to prepare Fairness Opinions in Switzerland.

About Vifor Pharma

‍Vifor Pharma is a globally active Swiss pharmaceutical company listed on the SIX Swiss Exchange. The company focuses on the development, manufacturing and marketing of pharmaceutical products in the areas of iron deficiency, nephrology and cardio-renal therapies.

The link to the official media release can be found here:
Media release

‍